Overview – Business Model

Alizé Pharma is a group of privately held biotech companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases.


Our team is composed of drug development experts and our management and board of directors offer wide international experience. Our strategy is to acquire early stage projects, typically at the discovery or preclinical stage, advance them into clinical development and establish partnerships with pharmaceutical companies to secure both near and long-term revenue streams. Since our creation in 2007, we have raised EUR 15.1 million from private and institutional investors. We have advanced two programs to the clinical phase and have also signed a first industrial partnership with Jazz Pharmaceuticals (Nasdaq: JAZZ).


Business Model and Corporate Organization

We operate under an asset-based business model and have pioneered this business model since 2007. This means that each program is developed within a dedicated company which is independently funded, thus providing investors with return on a project-by project basis.




Alizé pharma business model


As of 2014, there are 3 Alizé Pharma companies, each developing its own program

  • Alizé Pharma SAS, is working on a peptide derived from unacylated ghrelin (AZP­531). This program is in Phase II clinical development for the treatment of Prader-Willi syndrome and in Phase Ib for type 2 diabetes.
  • Alizé Pharma II SAS is focusing on the development of pegcrisantaspase  (Asparec® / JZP-416), a new pegylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia (ALL). It is partnered with Jazz Pharmaceuticals (Nasdaq: JAZZ) and is in Phase II/III clinical development.
  • Alizé Pharma III SAS has acquired exclusive worldwide rights on a family of new peptides with bone anabolic properties, to be developed in osteoporosis and other bone diseases. The I-HBD1 program is at the lead optimization stage.



Our Investors

The group has raised EUR 15.1 million from private and institutional investors since its creation. Participating investors in the financing rounds completed so far include the following:


initiative Octalfa, a Lyon-based independent investment company specializing in life sciences

Investor in Alizé Pharma, Alizé Pharma II and Alizé Pharma III


CEMA, a Canadian independent investment company

Investor in Alizé Pharma and Alizé Pharma II


Sham Innovation Santé, the investment arm of Sham, a Lyon-based insurance company specialized in medical malpractice liability insurance

Investor in Alizé Pharma, Alizé Pharma II and Alizé Pharma III


Bpifrance, the French Public Investment Bank, through the Innobio Fund

Investor in Alizé Pharma


Sofimac Partners via the FCPI Emergence Innovation 1 fund

Investor in AlizéPharma III

Rhône-Alpes création

Rhône-Alpes Création

Investor in Alizé Pharma III

Crédit Agricole

Crédit Agricole Création

Investor in Alizé Pharma III